Description

Simple

Clinical

Overview

Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

Pharmacology

Indication

Used mainly for sedation and hypnosis.

Pharmacodynamic

Information currently not available.

Mechanism of action

Heptabarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Heptabarbital
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
The therapeutic efficacy of Heptabarbital can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Heptabarbital is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acepromazine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Aceprometazine.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Heptabarbital.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Heptabarbital.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Heptabarbital may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Acotiamide
The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Acotiamide.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Heptabarbital.
Adipiplon
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Adipiplon.
Agmatine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Agmatine.
Agomelatine
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Agomelatine.
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Heptabarbital.
Alaproclate
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Alaproclate.